TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Variants in triggering receptor expressed on myeloid cells 2 (TREM2) confer high risk for Alzheimer’s disease (AD) and other neurodegenerative diseases. However, the cell types and mechanisms underlying TREM2’s involvement in neurodegeneration remain to be established. Here, we report that TREM2 is up-regulated on myeloid cells surrounding amyloid deposits in AD mouse models and human AD tissue. TREM2 was detected on CD45hiLy6C+ myeloid cells, but not on P2RY12+ parenchymal microglia. In AD mice deficient for TREM2, the CD45hiLy6C+ macrophages are virtually eliminated, resulting in reduced inflammation and ameliorated amyloid and tau pathologies. These data suggest a functionally important role for TREM2+ macrophages in AD pathogenesis and an unexpected, detrimental role of TREM2 in AD pathology. These findings have direct implications for future development of TREM2-targeted therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Trem2, a myeloid protein involved in microglial survival and proliferation, regulates a checkpoint necessary for DAM and deletion of Trem2 prevents microglial accumulation around Aβ plaques and leads to additional neuritic damage [6, 14–17].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [14]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“TREM2 was recently demonstrated to be essential for promoting microglial cell association with plaques44–49.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [45]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Although numerous studies have reported that TREM2 expression is upregulated in amyloid plaque-associated microglia in vivo (Frank et al., 2008; Jay et al., 2015), our research is the first to show that PU.1 knockdown abrogates this phenomenon in vitro.”
From PU.1 dictates β-amyloid-induced TREM2 expression upregulation in microglia in a transgenic model of Alzheimer’s disease (2025) · cites this paper as Jay et al., 2015
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Indeed, manipulation of expression of Trem2, Tyrobp, Cx3cl1/Cx3cr1, IL1β, and IFN-γ have all been shown to have opposing effects on amyloid and tau pathologies [49–51, 55–65].”
From Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways (2022) · cites this paper as [59]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss of TREM2 function in AD mouse models restricts the ability of microglia to surround Aβ plaques15,16, proliferate, and convert to DAM10,15,17, which in turn leads to more profound neuritic dystrophy18,19.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [16]
Experimental — accuracy not yet measured
34 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 2×
“5XFAD mice (The Jackson Laboratory B6SJL-Tg(APPSwFlLon,PSEN1*M146*l286V)) express mutant human APP(695) with Swedish (K670N/M671L), Florida (I716V), and London (V717I) mutations and human PSEN1 with M146L and L286V mutations under control of the Thy1 promoter (Oakley et al., 2006).”
BackgroundTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“Notably, variants of the immune cell– specific triggering receptor expressed on myeloid cells 2 (TREM2) confer dramatically elevated risk for developing AD (R. Guerreiro et al., 2013; Jonsson et al., 2013).”
BackgroundIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 3×
“First, we found that TREM2+ cells in AD mouse models 2013; Butovsky et al., 2014), was expressed by parenchymal, nonplaque-associated cells in APPPS1;Trem2+/+ mice (Fig.”
BackgroundSelf-citationIntegrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 2×
“TREM2, along with its obligate intracellular adaptor DAP12, was identified as a hub gene in systems biology analyses in AD (Forabosco et al., 2013; Zhang et al., 2013), highlighting the central importance of these myeloid cell signaling elements CORRESPONDENCE Bruce T.”
BackgroundThe microglial sensome revealed by direct RNA sequencing
Hickman, S. E., Kingery, N. D., Ohsumi, T. K., Borowsky, M. L., Wang, L.-C., Means, T. K., & El Khoury, J. (2013) · Nature Neuroscience · doi:10.1038/nn.3554 · Cited by 1,511
Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · cited 1×
“However, recent genome-wide association studies linked polymorphisms in inflammation-related genes to increased AD risk, supporting the conclusion that inflammation can be a causative factor in disease pathology (Karch and Goate, 2015).”
BackgroundMicroglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease
Prinz, M., & Priller, J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3722 · Cited by 1,329 · cited 1×
“The potential role of peripherally derived macrophages in AD has been controversial (Prinz and Priller, 2014), but it is well accepted that CD45hiLy6C+CCR2+ monocytes enter the central nervous system (CNS) and modulate pathology in other disease contexts (Mildner et al.”
BackgroundWyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Cited by
Items 401–500 of 683
Immune dysfunction in Alzheimer disease
Butovsky, O., Rosenzweig, N., Kleemann, K. L., Jorfi, M., Kuchroo, V. K., Tanzi, R. E., & Weiner, H. L. (2025) · Nature reviews. Neuroscience · doi:10.1038/s41583-025-00997-0 · Cited by 48
Self-citationType 1 Interleukin-4 Signaling Obliterates Mouse Astroglia in vivo but Not in vitro
Mashkaryan, V., Siddiqui, T., Popova, S. D., Coşacak, M. İ., Bhattarai, P., Brandt, K., Govindarajan, N., Petzold, A., Reinhardt, S., Dahl, A., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00114 · Cited by 28
Neurodegenerative phagocytes mediate synaptic stripping in Neuro-HIV
Liberto, G. D., Égervári, K., Kreutzfeldt, M., Schürch, C. M., Hewer, E., Wagner, I., Pasquier, R. D., & Merkler, D. (2022) · Brain · doi:10.1093/brain/awac102 · Cited by 28
Lu, Y., Huang, X., Liang, W., Li, Y., Xing, M., Pan, W., Zhang, Y., Wang, Z., & Song, W. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104688 · Cited by 28
Let’s make microglia great again in neurodegenerative disorders
Guillot‐Sestier, M., & Town, T. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1792-x · Cited by 31
“Conver- gent reports have shown that TREM2 is elevated by pla- que-associated mononuclear phagocytes in brains of AD model mice (Frank et al. 2008; Melchior et al. 2010; Jay et al. 2015).”
Knowledge gaps in Alzheimer's disease immune biomarker research
Morgan, D., & Mielke, M. M. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12342 · Cited by 27
Fatty acids as biomodulators of Piezo1 mediated glial mechanosensitivity in Alzheimer's disease
Ivković, S., Major, T., Mitić, M., Lončarević‐Vasiljković, N., Jović, M., & Adžić, M. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120470 · Cited by 29
Inhibition of TREM-2 Markedly Suppresses Joint Inflammation and Damage in Experimental Arthritis
Sigalov, A. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168857 · Cited by 31
“TREM-2 is widely thought to function as an immunomodulatory receptor, which negatively regulates inflammation [34,66,67].”
BackgroundKartjito, M. S., Yosia, M., Wasito, E., Soloan, G., Agussalim, A. A. K., & Basrowi, R. W. (2023) · Nutrients · doi:10.3390/nu15122642 · Cited by 45
TREM2 regulates microglial phagocytosis of synapses in innate immune tolerance
Meng, J., Han, L., Xu, H., Zhang, L., Liu, Z., Zhou, Y., Zhang, X., Luo, H., & Zhang, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111445 · Cited by 26
Maggiore, A., Latina, V., D’Erme, M., Amadoro, G., & Coccurello, R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102578 · Cited by 25
Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease
Kurnellas, M., Ghosn, E., Schartner, J. M., Baker, J. B., Rothbard, J. J., Negrin, R. S., Herzenberg, L. A., Fathman, C. G., Steinman, L., & Rothbard, J. B. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521206112 · Cited by 24
Xu, X., Du, L., Jiang, J., Yang, M., Wang, Z., Wang, Y., Tang, T., Fu, X., & Hao, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.716917 · Cited by 25
Microglia and microglial-based receptors in the pathogenesis and treatment of Alzheimer’s disease
Wang, Z., & Weaver, D. F. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109070 · Cited by 24
Clusterin/apolipoprotein J, its isoforms and Alzheimer's disease
Milinkeviciute, G., & Green, K. N. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1167886 · Cited by 27
“, 2015), activation (Jay et al., 2015; Wang et al., 2015), survival (Wang et al.”
Microglia in Alzheimer’s Disease
Süß, P., & Schlachetzki, J. C. M. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200212155234 · Cited by 27
An Alternatively Spliced TREM2 Isoform Lacking the Ligand Binding Domain is Expressed in Human Brain
Shaw, B. C., Snider, H. C., Turner, A. K., Zajac, D. J., Simpson, J. F., & Estus, S. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-215602 · Cited by 23
“crossed with amyloid-based AD models (APP/PS1 or 5xFAD mice) develop greater Aβ pathology [17, 18], but when crossed with the PS19 humantau-model, reduced tau pathology [9, 19].”
BackgroundEssex, A. L., Huot, J. R., Deosthale, P. J., Wagner, A., Figueras, J. H., Davis, A., Damrath, J. G., Pin, F., Wallace, J. M., Bonetto, A., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4572 · Cited by 26
“Previous work by Jay and colleagues((16,27)) have primarily used TREM2 knockoutmodels that do not express any TREM2 receptor to understand TREM2 signaling and consequences.”
BackgroundNoble, M., Scott‐Hewitt, N., & Folts, C. J. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.228712 · Cited by 23
“…are of active interest in respect to Alzheimer’s disease and potentially other neurodegenerative disorders (Jiang et al., 2013, 2014; Rohn, 2013; Jay et al., 2015; Lill et al., 2015; Lue et al., 2015; Painter et al., 2015; Poliani et al., 2015; Wang et al., 2015, 2016; Walter, 2016; Han et…”
BackgroundThe effect of Abi3 locus deletion on the progression of Alzheimer’s disease-related pathologies
Karahan, H., Smith, D. C., Kim, B., McCord, B., Mantor, J., John, S. K., Al-Amin, M. M., Dabin, L. C., & Kim, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1102530 · Cited by 20
“In the APP/PS1 mouse model, Trem2 deletion reduced Ab accumulation in 4-month-old mice (10).”
BackgroundPlasticity of human microglia and brain perivascular macrophages in aging and Alzheimer’s disease
Lee, D., Vicari, J. M., Porras, C., Spencer, C., Pjanic, M., Wang, X., Kinrot, S., Weiler, P., Kosoy, R., Bendl, J. M., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02716-6 · Cited by 36
Alterations of GABA B receptors in the APP/PS1 mouse model of Alzheimer's disease
Salazar, A., Osse, A. M. L., Ortiz, A. A., Murtishaw, A. S., & Kinney, J. W. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.10.013 · Cited by 26
Khan, M. I., Khan, M. Z., Shin, J. H., Shin, T. S., Lee, Y. B., Kim, M. Y., & Kim, J. D. (2022) · Molecules · doi:10.3390/molecules27072079 · Cited by 24
Hepatic TREM2 + macrophages express matrix metalloproteinases to control fibrotic scar formation
Lee, K., An, S., Kim, M., Kim, S. M., Jeong, W., Ko, H., Yang, Y. M., Noh, M., & Han, Y. (2023) · Immunology and Cell Biology · doi:10.1111/imcb.12616 · Cited by 25
Liu, N., Haziyihan, A., Zhao, W. G., Chen, Y., & Chao, H. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00434-9 · Cited by 28
“On the other hand, TREM2 also promotes inflammation in the middle and the late stages of AD [31, 37, 38].”
BackgroundVarnum, M. M., Clayton, K. A., Yoshii-Kitahara, A., Yonemoto, G., Koro, L., Ikezu, S., & Ikezu, T. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.759159 · Cited by 22
“APP PS1 mice expressing familial ADlinked variants of amyloid precursor protein (13) and presenilin-1 (PS1) show reduced accumulation of amyloid- peptide (A ) by disruption of TREM2 (23), whereas others report enhanced A clearance in 5XFAD mice lacking TREM2 (24).”
BackgroundResultIllouz, T., Madar, R., Biragyn, A., & Okun, E. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.10.004 · Cited by 22
“It is well established that the pathogenesis of AD, as well as of other neurodegenerative diseases, is tightly associated with microglial phenotype (Colonna and Butovsky, 2017; Jay et al., 2015; Keren-Shaul et al., 2017; Yin et al., 2017).”
von Saucken, V. E., Jay, T. R., & Landreth, G. E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105072 · Cited by 23
“To generate 5XFAD;Trem2−/− mice, we crossed 5XFAD mice to Trem2−/− mice (TREM2tm1(KOMP)Vlcg), which substitutes a lacZ reporter for exons 2, 3 and a part of exon 4 of Trem2 (Jay et al., 2015).”
InfluentialSelf-citationLi, X., Tang, X., Zeng, J., Duan, L., Hou, Z., Li, L., Guo, Y., Chai, C., Liu, J., Wang, Y., et al. (2026) · Cell · doi:10.1016/j.cell.2025.12.020 · Cited by 32
Takatori, S., Kondo, M., & Tomita, T. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00383-4 · Cited by 29
γ‐Secretase in microglia – implications for neurodegeneration and neuroinflammation
Walter, J., Kemmerling, N., Wunderlich, P., & Glebov, K. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14224 · Cited by 25
Pathways linking Alzheimer’s disease risk genes expressed highly in microglia
Hodges, A. K., Piers, T. M., Collier, D., Cousins, O., & Pocock, J. M. (2021) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2020.60 · Cited by 21
“In Tau-driven models, the picture is more complex with some studies showing loss of TREM2 to be protective in the presence of Tau pathology([124,125]) while others show it leads to worse outcomes([126,127]).”
Quan, W., Luo, Q., Hao, W., Tomic, I., Furihata, T., Schulz‐Schaeffer, W., Menger, M. D., Fassbender, K. C., & Liu, Y. (2021) · Glia · doi:10.1002/glia.24007 · Cited by 20
“One group reported that TREM2 deficiency in APP- transgenic mice increases hippocampal Aβ burden and accelerates neuron loss (Y. Wang et al., 2015), while another group showed that TREM2 deletion reduces cerebral Aβ accumulation (Jay et al., 2015).”
BackgroundStoiljković, M., Gutierrez, K. O., Kelley, C., Horváth, T. L., & Hajós, M. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210041 · Cited by 22
Beckmann, N., Neuhaus, A., Zurbruegg, S., Volkmer, P., Patiño, C., Joller, S., Feuerbach, D., Doelemeyer, A., Schweizer, T., Rudin, S., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02671-z · Cited by 25
APOEε4 and risk of Alzheimer’s disease – time to move forward
Lefterov, I. M., Fitz, N. F., Lü, Y., & Koldamova, R. P. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1195724 · Cited by 25
Španić, E., Leko, M. B., Horvat, L. L., Brgić, K., Vogrinc, Ž., Boban, M., Klepac, N., Borovečki, F., & Šimić, G. (2023) · Neurology International · doi:10.3390/neurolint15030053 · Cited by 21
“In contrast, one study discovered that the AD mouse model TREM2 knock-out (APPPS1; Trem2−/−) has decreased expression of the pro-inflammatory cytokines IL-1β and IL-6 and increased expression of anti-inflammatory markers associated with reduced Aβ and tau protein pathological alterations [22].”
ResultHotspots and trends of microglia in Alzheimer's disease: a bibliometric analysis during 2000–2022
Zhang, L., Yao, Q., Hu, J., Qiu, B., Xiao, Y., Zhang, Q., Zeng, Y., Zheng, S., Zhang, Y., Wan, Y., et al. (2024) · European journal of medical research · doi:10.1186/s40001-023-01602-9 · Cited by 24
Stoyanov, S., Sun, W., Düsedau, H. P., Cangalaya, C., Choi, I., Mirzapourdelavar, H., Baidoe‐Ansah, D., Kaushik, R., Neumann, J. H. L., Dunay, I. R., et al. (2020) · Glia · doi:10.1002/glia.23894 · Cited by 23
“Our data are thus complementary to a number of genetic studies (Jay et al., 2015; Wang et al., 2015) that focused on TREM2 expression on myeloid cells and microglia in amyloid pathology.”
ResultEmerging contributions of formyl peptide receptors to neurodegenerative diseases
Busch, L., Vieten, S., Brödel, S., Endres, K., & Bufe, B. (2021) · Biological Chemistry · doi:10.1515/hsz-2021-0258 · Cited by 23
Kilian, J., Hsu, H.-W., Mata, K., Wolf, F. W., & Kitazawa, M. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.02.011 · Cited by 25
Reprint of: Microglial toll-like receptors and Alzheimer’s disease
Su, F., Bai, F., Zhou, H., & Zhang, Z. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.05.016 · Cited by 20
CSF sTREM2 and Tau Work Together in Predicting Increased Temporal Lobe Atrophy in Older Adults
Halaas, N. B., Henjum, K., Blennow, K., Dakhil, S., Idland, A., Nilsson, L. N. G., Sederevičius, D., Dídac Vidal-piñeiro, A., Walhovd, K. B., Wyller, T. B., et al. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz240 · Cited by 21
TREM2-Deficient Microglia Attenuate Tau Spreading In Vivo
Lee-Gosselin, A., Jury-Garfe, N., You, Y., Dabin, L., Soni, D., Dutta, S., Rochet, J.-C., Kim, J., Oblak, A. L., & Lasagna-Reeves, C. A. (2023) · Cells · doi:10.3390/cells12121597 · Cited by 23
Microglia are SYK of Aβ and cell debris
Schafer, D. P., & Stillman, J. M. (2022) · Cell · doi:10.1016/j.cell.2022.09.043 · Cited by 18
Ayyubova, G. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.15914 · Cited by 23
Joshi, P., Riffel, F., Kumar, S., Villacampa, N., Theil, S., Parhizkar, S., Haass, C., Colonna, M., Heneka, M. T., Arzberger, T., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01263-x · Cited by 18
Deletion of Abi3/Gngt2 influences age-progressive amyloid β and tau pathologies in distinctive ways
Ibanez, K. R., McFarland, K. N., Phillips, J., Allen, M., Lessard, C. B., Zobel, L., De La Cruz, E. G., Shah, S., Vo, Q., Wang, X., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01044-1 · Cited by 18
Peng, W., Xie, Y., Liao, C., Bai, Y., Wang, H., & Li, C. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.966153 · Cited by 17
“Even though its protective and harmful roles during the pathogenesis of AD remain incompletely defined (Jay et al., 2015; Wang et al., 2015; Zhong et al., 2019), increasing evidence suggest that TREM2 is closely related to microgliosis, astrogliosis, neuroinflammation, neuronal loss and cognition impairment in AD (Jay…”
BackgroundAlzheimer’s disease: an axonal injury disease?
Liang, D., & Zhang, Z. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1264448 · Cited by 23
Yadav, V., Mythri, C., & Kumarasamy, M. (2024) · Brain Behavior and Immunity Integrative · doi:10.1016/j.bbii.2024.100048 · Cited by 26
Hall, S. C., & Agrawal, D. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-12330-6 · Cited by 23
Hematogenous Macrophages: A New Therapeutic Target for Spinal Cord Injury
Ding, Y., Zhang, D., Wang, S., Zhang, X., & Yang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.767888 · Cited by 20
Guo, X., Liu, Y., Morgan, D., & Zhao, L.-R. (2020) · Aging and Disease · doi:10.14336/ad.2020.0201 · Cited by 15
Ennerfelt, H. E., Holliday, C., Shapiro, D. A., Zengeler, K. E., Bolte, A. C., Ulland, T. K., & Lukens, J. R. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303760120 · Cited by 17
Wieczorek, K., Markiewicz, M., Walczewska, A., & Zgórzyńska, E. (2023) · Cellular Physiology and Biochemistry · doi:10.33594/000000668 · Cited by 17
Perturbation of the transcriptome: implications of the innate immune system in Alzheimer's disease
Song, F., Qian, Y., Peng, X., Han, G., Wang, J., Bai, Z., Crack, P. J., & Lei, H. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.09.015 · Cited by 17
Regulatable Lentiviral Hematopoietic Stem Cell Gene Therapy in a Mouse Model of Parkinson's Disease
Ge, G., Chen, C., Guderyon, M. J., Liu, J., He, Z.-X., Yu, Y., Clark, R. A., & Li, S.-L. (2018) · Stem Cells and Development · doi:10.1089/scd.2018.0030 · Cited by 15
Braun, D. J., Dimayuga, E. R., Morganti, J. M., & Eldik, L. J. V. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01938-7 · Cited by 18
Role of triggering receptor expressed on myeloid cells 2 (TREM2) in neurodegenerative dementias
Shafi, S., Singh, A., Ibrahim, A. M., Alhajri, N., Izneid, T. A., & Pottoo, F. H. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15215 · Cited by 15
Han, S., Na, Y., Koh, I., Nho, K. T., & Lee, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189865 · Cited by 18
“This result is consistent with prior knowledge of TREM2, which is well-documented, to be important for immune function in AD [5,7,8,42].”
ResultWeller, A. E., Ferraro, T. N., Doyle, G. A. R., Reiner, B. C., Crist, R. C., & Berrettini, W. H. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220391 · Cited by 17
Pankiewicz, J. E., Lizińczyk, A. M., Franco, L. A., Diaz, J. R., Martá-Ariza, M., & Sadowski, M. J. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01261-z · Cited by 15
“Microglia in Trem2−/− mice were shown not to transit to the MGnD, while lack of Apoe expression reduces neurodegeneration of the facial nerve nucleus following the VII nerve axotomy [36, 41, 45].”
BackgroundAmyloid β-Induced Inflammarafts in Alzheimer’s Disease
Ding, S., Choi, S., & Miller, Y. I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104592 · Cited by 24
“In AD, TREM2 expression is notably upregulated, particularly in microglia surrounding A β plaques [67].”
VEGF controls microglial phagocytic response to amyloid-β
Gea, P. D., Benkeder, S., Bouvet, P., Aimard, M., Chounlamountri, N., Honnorat, J., Do, L.-D., & Meissirel, C. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1264402 · Cited by 19
Loss of TREM2 diminishes CAA despite an overall increase of amyloid load in Tg‐SwDI mice
Zhong, R., Xu, Y., Williams, J. W., & Li, L. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14222 · Cited by 16
Checkpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous System
Harrison‐Brown, M., Liu, G. J., & Banati, R. B. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122030 · Cited by 17
“Although animal models report seemingly conflicting effects of eliminating or overexpressing Trem2 [113,114], and the relative contribution of peripheral and CNS-resident cells is yet to be investigated, most studies agree that the receptor (and by extension, myeloid cells) plays an important role in the response to d…”
BackgroundMultitasking Microglia and Alzheimer’s Disease: Diversity, Tools and Therapeutic Targets
Grubman, A., Kanninen, K. M., & Malm, T. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0825-5 · Cited by 16
“Aside from the controversy regarding the identity of TREM2 cells (Jay et al. 2015), a number of questions remain unaddressed: do TREM2 microglia perform distinct physiological functions and what effect do TREM2mutations”
BackgroundInfluentialMishra, S., Swain, P. S., Pati, S., & Dehury, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41414 · Cited by 17
Pilat, D. J., Le, H., Prokopenko, D., Lin, C.-C. J., Eimer, W. A., Quinti, L., Gavrilles, E. P., Garcia, S. N., Heitman, S. N., McGinty, D., et al. (2026) · Neuron · doi:10.1016/j.neuron.2025.09.032 · Cited by 14
MEK1/2 activity modulates TREM2 cell surface recruitment
Schapansky, J., Grinberg, Y. Y., Osiecki, D. M., Freeman, E. A., Walker, S. G., Karran, E. H., Gopalakrishnan, S. M., & Talanian, R. V. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014352 · Cited by 15
Role of TREM2 in the Development of Neurodegenerative Diseases After Traumatic Brain Injury
Zhang, C., & Chen, S. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03094-w · Cited by 14
Apolipoprotein ε in Brain and Retinal Neurodegenerative Diseases
Abyadeh, M., Gupta, V., Paulo, J. A., Sheriff, S., Shadfar, S., Fitzhenry, M. J., Amirkhani, A., Gupta, V. B., Salekdeh, G. H., Haynes, P. A., et al. (2024) · Aging and Disease · doi:10.14336/ad.2023.0312-1 · Cited by 28
Gui, J., Liu, J., Wang, L., Luo, H., Huang, D., Yang, X., Song, H., Han, Z., Ding, R., Yang, J., et al. (2023) · Environmental Science and Pollution Research · doi:10.1007/s11356-023-30764-6 · Cited by 15
“In the central nervous system, TREM2 is primarily expressed in microglia (Jay et al. 2015).”
BackgroundVandermeulen, L., Geric, I., Fumagalli, L., Kreir, M., Lu, A., Nonneman, A., Premereur, J., Wolfs, L., Policarpo, R., Fattorelli, N., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00725-9 · Cited by 18
Henningfield, C. M., Soni, N., Lee, R. W., Sharma, R. B., Cleland, J. L., & Green, K. N. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01470-3 · Cited by 19
“Previous research that involved knocking out, knocking down, or overexpressing TREM2 or its downstream effectors has emphasized the crucial role of TREM2 in promoting microglial association with plaques [17, 18, 26, 27, 33, 34, 54, 68].”
BackgroundResultYassaghi, Y., Nazerian, Y., Ghasemi, M., Nazerian, A., Sayehmiri, F., Perry, G. L., & Pourbadie, H. G. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18554 · Cited by 15
“TREM2 deficiency increased plaque burden in the 5XFAD 128 but unexpectedly decreased amyloid burden in the APPPS1-21 model, 129 possibly due to a shift toward anti-inflammatory processes in the TREM2-deficient myeloid cells model.”
BackgroundKawahara, K., Hirata, H., Ohbuchi, K., Nishi, K., Maeda, A., Kuniyasu, A., Yamada, D., Maeda, T., Tsuji, A., Sawada, M., et al. (2016) · Glia · doi:10.1002/glia.23034 · Cited by 15
Uddin, M. S., Kabir, M. T., Mamun, A. A., Behl, T., Mansouri, R. A., Aloqbi, A. A., Perveen, A., Hafeez, A., & Ashraf, G. M. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200531151004 · Cited by 18
Knight, A. C., Brill, S. A., Solis, C. V., Richardson, M. R., McCarron, M. E., Queen, S. E., Bailey, C. C., & Mankowski, J. L. (2020) · Journal of NeuroVirology · doi:10.1007/s13365-020-00844-1 · Cited by 16
“However, long-term activation of TREM2 can also contribute to neurodegenerative diseases, suggesting that the role of TREM2 signaling in neurodegeneration is time dependent (Jay et al. 2015).”
Fighting fire with fire: The immune system might be key in our fight against Alzheimer’s disease
Dujardin, P., Vandenbroucke, R. E., & Hoecke, L. V. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.01.004 · Cited by 15
Martins, S., Müller‐Schiffmann, A., Erichsen, L., Bohndorf, M., Wruck, W., Sleegers, K., Broeckhoven, C. V., Korth, C., & Adjaye, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124516 · Cited by 14
Rocha, N. K. R., Themoteo, R. M., Brentani, H., Forlenza, O. V., & de Paula, V. D. J. R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.579984 · Cited by 14
“…by AD pathogenesis—by the recruitment of monocytes and subsequent modifications in tissue-resident microglia in the central nervous system (Lai and McLaurin, 2012; Guillot-Sestier et al., 2015; Jay et al., 2015; Koronyo et al., 2015; Matcovitch-Natan et al., 2016; Deardorff and Grossberg, 2017).”
BackgroundNand, S., Chaturvedi, V. K., Singh, S. P., & Singh, M. P. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00219 · Cited by 14
“On other hand, in Trem2-deficient Alzheimer disease (AD) mice, status of neurofibrillary tangles remains uncertain; it may either increase or decrease (Jay et al., 2015; Wang et al., 2016).”
BackgroundNjoku, G. C., & Kanmogne, G. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189069 · Cited by 15
“At four months, cortical A β levels remained unchanged, while hippocampal A β levels decreased [118]; by eight months, cortical A β burden increased, while hippocampal levels showed no further change [119].”
Estimation of blood-based biomarkers of glial activation related to neuroinflammation
Yasuno, F., Watanabe, A., Kimura, Y., Yamauchi, Y., Ogata, A., Ikenuma, H., Abe, J., Minami, H., Nihashi, T., Yokoi, K., et al. (2022) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2022.100549 · Cited by 12
Myeloid masquerade: Microglial transcriptional signatures in retinal development and disease
Pitts, K. M., & Margeta, M. A. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1106547 · Cited by 14
“Considering persistent overlaps in microglial marker expression by different myeloid cell subpopulations, resolving the ontogeny of the DAM population has been a matter of some debate (Jay et al., 2015; Van Hove et al., 2019; Silvin et al., 2022).”
BackgroundVar, S. R., Strell, P., Johnson, S. T., Roman, A., Vasilakos, Z., & Low, W. C. (2023) · Cell Transplantation · doi:10.1177/09636897231171001 · Cited by 15
Sharo, C., Zhai, T., & Huang, Z. J. (2024) · Pharmaceuticals · doi:10.3390/ph17010137 · Cited by 13
“The triggering receptor expressed on myeloid cells 2 (TREM2) has also been proven to play a key role in the correlation between chronic inflammation and Alzheimer’s pathogenesis [6,21,73].”
BackgroundTherapeutic Targets in Innate Immunity to Tackle Alzheimer’s Disease
Serradas, M. L., Ding, Y., Martorell, P., Kulińska, I., & Castro‐Gomez, S. (2024) · Cells · doi:10.3390/cells13171426 · Cited by 17
“Despite these contradictions, there is a consensus that Trem2 deficiency reduces microglia cell accumulation around plaques and attenuates inflammation-related gene expression [98,99,102].”
BackgroundMiao, Y., Wang, N., Shao, W., Xu, Z., Yang, Z., Wang, L., Ju, C., Zhang, R., & Zhang, F. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09861-2 · Cited by 14
Wang, W., Li, T., Wang, Z., Yin, Y., Zhang, S., Wang, C., Hu, X., & Lu, S. (2023) · iScience · doi:10.1016/j.isci.2023.107833 · Cited by 14
Pumo, A., & Legeay, S. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148817 · Cited by 14
“…have demonstrated that TREM2-deficient microglia are no longer able to gather or proliferate around plaques, do not show the morphological changes typical of microglial activation, and experience increased cell death (Jay et al., 2015; Wang et al., 2015; Cantoni et al., 2015; Ulrich et al., 2014).”
BackgroundAli, M., Garcia, P., Lunkes, L. P., Sciortino, A., Thomas, M. H., Heurtaux, T., Grzyb, K., Halder, R., Coowar, D., Skupin, A., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01885-9 · Cited by 21
Cómitre-Mariano, B., Vellila-Alonso, G., Segura‐Collar, B., Mondéjar-Ruescas, L., Sepúlveda-Sánchez, J. M., & Gargini, R. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03298-y · Cited by 16
“TREM2 deficiency results in a reduced microglial response to Aβ and worsened plaque pathology, suggesting that TREM2 is critical for the protective functions of microglia in AD [79].”
Baranger, K., van Gijsel‐Bonnello, M., Stephan, D., Carpentier, W., Rivera, S., Khrestchatisky, M., Gharib, B., Reggi, M. L. D., & Benech, P. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00754-z · Cited by 15
Kozyrev, N., Albers, S. S., Yang, J., Prado, V. F., Prado, M. A. M., Fonseca, G. J., Rylett, R. J., & Dekaban, G. A. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlaa093 · Cited by 14
Functional insight into LOAD-associated microglial response genes
Jonas, L. A., Jain, T., & Li, Y. (2022) · Open Biology · doi:10.1098/rsob.210280 · Cited by 16
Theerasri, A., Janpaijit, S., Tencomnao, T., & Prasansuklab, A. (2022) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1591 · Cited by 14
Microglial cGAS deletion protects against amyloid-β induced Alzheimer’s disease pathogenesisPreprint
He, S., Li, X., Mittra, N., Bhattacharjee, A., Wang, H., Zhao, S., Liu, F., & Han, X. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.07.552300 · Cited by 12
Metadata
- Authors
- Jay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., Cotleur, A. C., Butovsky, O., Bekris, L., Staugaitis, S. M., Leverenz, J. B., Pimplikar, S. W., Landreth, G. E., Howell, G. R., Ransohoff, R. M., & Lamb, B. T.
- Affiliations
- Cleveland Clinic (US)
- The Lerner Research Institute 1 and 2
- Jackson Laboratory (US)
- Case Western Reserve University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Lamb, Bruce T.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-03-02
- Volume
- 212
- Issue
- 3
- Pages
- 287-295
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4354365
- OpenAlex
- W2155344647
- Cited by
- 682
- References
- 33
- Citations by year
- 2026: 27 · 2025: 56 · 2024: 46 · 2023: 56 · 2022: 74 · 2021: 62 · 2020: 70 · 2019: 59 · 2018: 65 · 2017: 67 · 2016: 54 · 2015: 45
- FWCI
- 41.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (UL1TR000439)
- National Institute on Aging (R01AG023012, AG023012, F31AG048704)
- National Institute of General Medical Sciences (T32GM007250)
- National Institute of Neurological Disorders and Stroke (NS047804, T32NS067431, NS087298, R01NS088137, T32NS077888)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- TREM2, Alzheimer's disease, inflammatory macrophages, microglia, amyloid deposits, tau pathology, neuroinflammation, amyloidosis
- MeSH terms
- Age Factors, Aged, Alzheimer Disease, Animals, Disease Models, Animal, Female, Hippocampus, Humans, Macrophages, Male, Membrane Glycoproteins, Mice, Transgenic, Receptors, Immunologic, Up-Regulation, Amyloid beta-Peptides, tau Proteins, Leukocyte Common Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.